SG11201600379TA - Polyconjugates for delivery of rnai triggers to tumor cells in vivo - Google Patents
Polyconjugates for delivery of rnai triggers to tumor cells in vivoInfo
- Publication number
- SG11201600379TA SG11201600379TA SG11201600379TA SG11201600379TA SG11201600379TA SG 11201600379T A SG11201600379T A SG 11201600379TA SG 11201600379T A SG11201600379T A SG 11201600379TA SG 11201600379T A SG11201600379T A SG 11201600379TA SG 11201600379T A SG11201600379T A SG 11201600379TA
- Authority
- SG
- Singapore
- Prior art keywords
- polyconjugates
- vivo
- delivery
- tumor cells
- rnai triggers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
- C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3535—Nitrogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361863056P | 2013-08-07 | 2013-08-07 | |
PCT/US2014/049851 WO2015021092A1 (en) | 2013-08-07 | 2014-08-06 | Polyconjugates for delivery of rnai triggers to tumor cells in vivo |
US14/452,626 US9487556B2 (en) | 2013-08-07 | 2014-08-06 | Polyconjugates for delivery of RNAi triggers to tumor cells in vivo |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201600379TA true SG11201600379TA (en) | 2016-02-26 |
Family
ID=52449177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201600379TA SG11201600379TA (en) | 2013-08-07 | 2014-08-06 | Polyconjugates for delivery of rnai triggers to tumor cells in vivo |
Country Status (14)
Country | Link |
---|---|
US (3) | US9487556B2 (ko) |
EP (1) | EP3030244B1 (ko) |
JP (1) | JP6433001B2 (ko) |
KR (1) | KR20160035081A (ko) |
CN (1) | CN105451743B (ko) |
AU (1) | AU2014306021B2 (ko) |
CA (1) | CA2919088A1 (ko) |
EA (1) | EA201690051A1 (ko) |
HK (1) | HK1220397A1 (ko) |
IL (1) | IL243941B (ko) |
MX (1) | MX2016001006A (ko) |
SG (1) | SG11201600379TA (ko) |
TW (1) | TWI685347B (ko) |
WO (1) | WO2015021092A1 (ko) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9487556B2 (en) * | 2013-08-07 | 2016-11-08 | Arrowhead Pharmaceuticals, Inc. | Polyconjugates for delivery of RNAi triggers to tumor cells in vivo |
AU2016233364A1 (en) * | 2015-03-17 | 2017-09-21 | Arrowhead Pharmaceuticals, Inc. | Compositions and methods for inhibiting gene expression of factor Xll |
CN107635550B (zh) * | 2015-03-17 | 2021-12-24 | 箭头药业股份有限公司 | 改良的含二硫化物的炔烃交联剂 |
JP7021076B2 (ja) | 2015-05-29 | 2022-02-16 | アローヘッド ファーマシューティカルズ インコーポレイテッド | Hif2αの遺伝子発現を阻害する組成物及び方法 |
WO2016196243A1 (en) | 2015-05-29 | 2016-12-08 | Arrowhead Pharmaceuticals, Inc. | Biologically cleavable tetrapeptide linking agents |
JP7015784B2 (ja) | 2015-12-29 | 2022-02-15 | ガルデルマ エス.エー. | 炭水化物架橋剤 |
EP3252082A1 (en) * | 2016-05-31 | 2017-12-06 | Galderma S.A. | Method for deacetylation of biopolymers |
PT3623390T (pt) * | 2016-05-31 | 2023-10-27 | Galderma Sa | Reticulador de hidrato de carbono |
WO2019210200A1 (en) | 2018-04-27 | 2019-10-31 | Arrowhead Pharmaceuticals, Inc. | Integrin targeting ligands and uses thereof |
CN110240551B (zh) * | 2019-06-25 | 2022-02-11 | 成都郑源生化科技有限公司 | Fmoc-β-Ala-Gly-OH的制备方法 |
WO2021111303A1 (en) | 2019-12-02 | 2021-06-10 | Galderma Holding SA | High molecular weight esthetic compositions |
CN113004515B (zh) * | 2021-03-02 | 2023-02-24 | 厦门大学附属中山医院 | 一种仿透明质酸聚氨基酸衍生物、其制备方法及其应用 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9610422A (pt) * | 1995-08-30 | 1999-07-13 | Searle & Co | Derivados de meta-guanidina uréia tiouréia ou ácido aminobenzóico azacíclico como antagonistas de integrina |
WO1997036862A1 (en) | 1996-03-29 | 1997-10-09 | G.D. Searle & Co. | META-SUBSTITUTED PHENYLENE DERIVATIVES AND THEIR USE AS ALPHAvBETA3 INTEGRIN ANTAGONISTS OR INHIBITORS |
JP2001501600A (ja) * | 1996-09-10 | 2001-02-06 | ザ バーナム インスティテュート | 腫瘍ホーミング分子、それに由来する結合体、およびその使用方法 |
EP0870756B1 (fr) | 1997-04-07 | 2001-11-07 | Cfpi Nufarm | Procédé de préparation des dinitroanilines 3,4-disubstituées |
CN1606566A (zh) * | 2001-10-22 | 2005-04-13 | 斯克里普斯研究学院 | 整联蛋白靶向化合物 |
JP2004261024A (ja) * | 2003-02-28 | 2004-09-24 | Japan Science & Technology Agency | ペプチド修飾多糖類を用いる遺伝子治療剤 |
JP2006522158A (ja) * | 2003-04-03 | 2006-09-28 | アルナイラム ファーマシューティカルズ インコーポレイテッド | iRNA複合体 |
US8084599B2 (en) | 2004-03-15 | 2011-12-27 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
AU2005304816A1 (en) * | 2004-11-04 | 2006-05-18 | Raul Andino | Syntheses of polyamine conjugates of small interfering RNAs (si-RNAs) and conjugates formed thereby |
MX2007012766A (es) * | 2005-04-12 | 2008-10-01 | Intradigm Corp | Composición y métodos de terapéuticos de arni para el tratamiento de cáncer y otras enfermedades de neovascularización. |
BRPI0715375A2 (pt) | 2006-08-18 | 2013-06-18 | Hoffmann La Roche | policonjugados para distribuiÇço in vivo de polinucleotÍdeos |
US8017109B2 (en) | 2006-08-18 | 2011-09-13 | Roche Madison Inc. | Endosomolytic poly(acrylate) polymers |
BRPI0716823A2 (pt) * | 2006-09-15 | 2015-05-26 | Enzon Pharmaceuticals Inc | Conjunto poliméricos contendo porções positivamente carregadas |
WO2008045252A2 (en) | 2006-10-04 | 2008-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Engineered integrin binding peptides |
WO2010080129A2 (en) | 2008-12-18 | 2010-07-15 | Dicerna Pharmaceuticals, Inc. | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
US20100249214A1 (en) | 2009-02-11 | 2010-09-30 | Dicerna Pharmaceuticals | Multiplex dicer substrate rna interference molecules having joining sequences |
EP3023495B1 (en) | 2010-02-24 | 2019-05-08 | Arrowhead Pharmaceuticals, Inc. | Compositions for targeted delivery of sirna |
US8501930B2 (en) * | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
CN104328121A (zh) | 2010-12-29 | 2015-02-04 | 弗·哈夫曼-拉罗切有限公司 | 用于细胞内递送核酸的小分子缀合物 |
SG189942A1 (en) * | 2010-12-29 | 2013-06-28 | Arrowhead Res Corp | In vivo polynucleotide delivery conjugates having enzyme sensitive linkages |
CA2842039A1 (en) | 2011-08-26 | 2013-03-07 | Arrowhead Research Corporation | Poly(vinyl ester) polymers for in vivo nucleic acid delivery |
CN104039356B (zh) | 2012-01-27 | 2018-08-17 | 弗·哈夫曼-拉罗切有限公司 | 用于靶向递送的、与小分子整联蛋白拮抗剂共价连接的壳聚糖 |
JP6316209B2 (ja) * | 2012-01-27 | 2018-04-25 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | αVβ3を発現する細胞への標的化送達のためのインテグリンアンタゴニスト結合体 |
CN103764153A (zh) | 2012-04-18 | 2014-04-30 | 箭头研究公司 | 用于体内核酸递送的聚(丙烯酸酯)聚合物 |
US9487556B2 (en) * | 2013-08-07 | 2016-11-08 | Arrowhead Pharmaceuticals, Inc. | Polyconjugates for delivery of RNAi triggers to tumor cells in vivo |
-
2014
- 2014-08-06 US US14/452,626 patent/US9487556B2/en active Active
- 2014-08-06 MX MX2016001006A patent/MX2016001006A/es unknown
- 2014-08-06 SG SG11201600379TA patent/SG11201600379TA/en unknown
- 2014-08-06 EA EA201690051A patent/EA201690051A1/ru unknown
- 2014-08-06 CN CN201480044362.9A patent/CN105451743B/zh active Active
- 2014-08-06 JP JP2016533388A patent/JP6433001B2/ja active Active
- 2014-08-06 CA CA2919088A patent/CA2919088A1/en not_active Abandoned
- 2014-08-06 KR KR1020167005887A patent/KR20160035081A/ko not_active Application Discontinuation
- 2014-08-06 AU AU2014306021A patent/AU2014306021B2/en active Active
- 2014-08-06 EP EP14834389.0A patent/EP3030244B1/en active Active
- 2014-08-06 WO PCT/US2014/049851 patent/WO2015021092A1/en active Application Filing
- 2014-08-07 TW TW103127144A patent/TWI685347B/zh active
-
2016
- 2016-02-03 IL IL243941A patent/IL243941B/en active IP Right Grant
- 2016-07-19 HK HK16108574.9A patent/HK1220397A1/zh unknown
- 2016-09-28 US US15/278,518 patent/US20170022497A1/en not_active Abandoned
-
2018
- 2018-11-13 US US16/189,550 patent/US20190062748A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2015021092A1 (en) | 2015-02-12 |
TW201601742A (zh) | 2016-01-16 |
CN105451743A (zh) | 2016-03-30 |
AU2014306021A2 (en) | 2016-11-24 |
US9487556B2 (en) | 2016-11-08 |
JP2016535058A (ja) | 2016-11-10 |
MX2016001006A (es) | 2016-04-19 |
CN105451743B (zh) | 2019-11-19 |
US20150045573A1 (en) | 2015-02-12 |
EP3030244B1 (en) | 2021-04-21 |
EP3030244A4 (en) | 2017-06-28 |
KR20160035081A (ko) | 2016-03-30 |
EA201690051A1 (ru) | 2016-06-30 |
US20190062748A1 (en) | 2019-02-28 |
US20170022497A1 (en) | 2017-01-26 |
HK1220397A1 (zh) | 2017-05-05 |
IL243941B (en) | 2019-06-30 |
AU2014306021B2 (en) | 2018-12-13 |
JP6433001B2 (ja) | 2018-12-05 |
IL243941A0 (en) | 2016-04-21 |
TWI685347B (zh) | 2020-02-21 |
CA2919088A1 (en) | 2015-02-12 |
AU2014306021A1 (en) | 2016-01-28 |
EP3030244A1 (en) | 2016-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1220397A1 (zh) | 用於在活體中遞送 觸發子至腫瘤細胞的聚偶聯物 | |
IL244113A0 (en) | Selective delivery of substance to cells | |
HK1206639A1 (en) | In vivo production of proteins | |
EP2971013A4 (en) | LIPID NANOPARTICLES FOR TRANSFECTION AND ASSOCIATED METHODS | |
HK1245834A1 (zh) | 一種b細胞用於體內遞送治療劑 | |
EP2872036A4 (en) | IN VIVO BIOSENSOR | |
EP2941243A4 (en) | SURFACE BINDING IN THE ADMINISTRATION OF A MEDICAMENT ON NANOPARTICLE BASE IN A TISSUE | |
EP2972950A4 (en) | SEGMENTATION OF CONTENT DISTRIBUTION | |
HK1205185A1 (en) | Methods and composition related to brown adipose-like cells | |
HK1205758A1 (en) | Rnai agents to treat beta catenin related diseases | |
EP2807555A4 (en) | PROCESSORS FOR PARA-VIRTUALIZED ASYMMETRIC GRAPHIC PROCESSING UNIT (GPU) | |
PL2925223T3 (pl) | Udoskonalone sposoby oceny funkcji metabolicznej | |
SG11201405110TA (en) | Cell preparation including fat cell | |
EP2661489A4 (en) | METHOD FOR INCREASING THE DELIVERY OF GEN-TRANSDUCED CELLS | |
EP2832038A4 (en) | INTELLIGENT DISTRIBUTION OF LEGAL INTERCEPTION DATA (LI) IN EMERGENCY CONDITIONS | |
AP2014008135A0 (en) | Improved endoglucanases for treatment of cellulosic material | |
GB201516123D0 (en) | In vivo cell imaging | |
EP3027739A4 (en) | MODIFIED CELLS FOR THE PRODUCTION OF BLOOD CELLS | |
SG11201502214PA (en) | Adipose tissue cells | |
PL3082858T3 (pl) | Środek wiążący adrenomedulinę do zastosowania w terapii nowotworu | |
EP2950663A4 (en) | METHOD FOR INCREASING THE SILAGE QUALITY OF USEFUL PLANTS | |
GB201302197D0 (en) | Method of increasing lipid accumulation in pulcherrima cells | |
GB201304514D0 (en) | Cell delivery | |
EP2994118A4 (en) | USE OF LAPPAOL F TO INHIBIT THE GROWTH OF TUMOR CELLS | |
EP2738248A4 (en) | METHOD FOR THE PRODUCTION OF VITRO VASCULARIZED TISSUE |